Related Experiment Video
Updated: Jun 22, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Comparative overview of safety of the biologics in rheumatoid arthritis
1Nexus Clinical Research, 1 Anderson Avenue, St. John's, NL A1B 3E1, Canada. mkhraish@mun.ca
Abstract:
Six biologic agents are currently available in Canada for the treatment of rheumatoid arthritis (RA): abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab. Although they are generally considered to be safe and well tolerated, concerns have been raised regarding the use of biologic therapies in the treatment of RA. The new biologic agents abatacept and rituximab have novel mechanisms of action, and may therefore offer different safety profiles. The most important safety concerns with the biologic therapies remain the increased risk of infection. An increased risk of malignancies, including lymphoma and skin cancer, has been noted in RA trials, but the extent to which each of the biologic therapies contributes to the risk of malignancy has not been clearly defined.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Bioequivalence studies: Biowaivers
Bioequivalence: Overview